



BEST AVAILABLE COPY

PTO/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/935,726-Conf. #3533		
		Filing Date	August 24, 2001		
		First Named Inventor	Jing-Shan Hu		
		Art Unit	1647		
		Examiner Name	R. Landsman		
Sheet	1	of	2	Attorney Docket Number	PF112P3D1C

RECEIVED

JUN 23 2003

TECH CENTER 1680/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	FR	Statutory Declaration of Kari Alitalo, executed on August 14, 2002, and accompanying Exhibits KA-1 and KA-2				
	FS	Statutory Declaration of Peter Adrian Walton Rogers, executed on August 9, 2002				
	FT	Statutory Declaration of Francis John Ballard, executed on July 16, 2002				
	FU	Statutory Declaration of Kari Alitalo, executed on July 16, 2002, and accompanying Exhibit 1				
	FV	Statutory Declaration of Susan Power, executed on March 22, 2002, and accompanying Appendices I to IV				
	FW	Statutory Declaration of Nicholas Kim Hayward, executed on March 26, 2002				
	FX	Statutory Declaration of Stuart A. Aaronson, executed on March 22, 2002, and accompanying Appendices I to III				
	FY	Statutory Declaration of Gary Baxter Cox, executed on March 22, 2002, and accompanying Exhibit GBC24 (Statutory Declaration of Peter Adrian Walters, executed on October 26, 2001)				
	PZ	Statutory Declaration of Frances John Ballard, executed on December 12, 2001, and accompanying Exhibit 1				
	GA	Statutory Declaration of Kari Alitalo, executed on September 24, 2001, and accompanying Exhibits 1 and 2				
	GB	Statutory Declaration of Peter Adrian Walton Rogers, executed on November 12, 2001, and accompanying Exhibits PAWR1 to PAWR14				
	GC	Statutory Declaration of John Stanley Mattick, executed on December 12, 2000, and accompanying Exhibits JSM1 to JSM4				
	GD	Statutory Declaration of Nicholas Kim Hayward, executed on December 8, 2000, and accompanying Exhibits NKH 1 and 2				

Examiner Signature	<i>Landsman</i>	Date Considered	9/6/05
-----------------------	-----------------	--------------------	--------

considered - do not print



PTO/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/935,726-Conf. #3533
			Filing Date	August 24, 2001
			First Named Inventor	Jing-Shan Hu
			Art Unit	1647
			Examiner Name	R. Landsman
			Attorney Docket Number	PF112P3D1C1
Sheet	2	of	2	

NON PATENT LITERATURE DOCUMENTS		
<input checked="" type="checkbox"/>	GE	Statutory Declaration of Jennifer Ruth Gamble, executed on December 12, 2000, and accompany Exhibits JRG 1 to 3
<input checked="" type="checkbox"/>	GF	Statutory Declaration of Tom Rapoport, executed on December 13, 2000, and accompanying Exhibits TP 1 and 2
<input checked="" type="checkbox"/>	GG	Statutory Declaration of Stuart A. Aaronson, executed on December 14, 2000, and accompanying CV
<input checked="" type="checkbox"/>	GH	Statutory Declaration of Susan Power, executed on December 13, 2000, and accompanying Appendices 1 to 2 and F161
<input checked="" type="checkbox"/>	GI	Statutory Declaration of Gary Baxter Cox, executed on December 13, 2000, and accompanying Exhibits GBC 1 to 23
<input checked="" type="checkbox"/>	GJ	Statutory Declaration of Peter Adrian Walton Rogers, executed on February 16, 2000, and accompanying Exhibit 1
<input checked="" type="checkbox"/>	GK	Statutory Declaration of Frances John Ballard, executed on February 16, 2000, and accompanying Exhibit 1
<input checked="" type="checkbox"/>	GL	Statutory Declaration of Karl Alitalo, executed on February 15, 2000, and accompanying Exhibits 1 to 3

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED
JUN 23 2003
TECH CENTER 1600/2900

Examiner Signature	<i>Qaithe</i>	Date Considered	9/6/05
--------------------	---------------	-----------------	--------

Please type a plus sign (+) inside this box ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0631-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 9

Complete if Known

Application Number 09/931,172
Filing Date August 2, 2001
First Named Inventor HU et al.
Group Art Unit 1647
Examiner Name Unassigned
Attorney Docket Number PF111P3D1C1



BEST AVAILABLE COPY

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ¹ (if known)		
M	AA	5,633,147		Meissner et al.	05-27-1999
	AB	5,283,354		Lemischka	02-01-1994
	AC	5,240,848		Keck et al.	08-31-1993
	AD	5,234,908		Szabo et al.	08-10-1993
	AE	5,194,596		Tischer et al.	03-16-1993
	AF	5,861,301		Terman et al.	01-19-1999
	AG	5,840,693		Eriksson et al.	11-24-1999
	AH	5,073,492		Chen et al.	12-17-1991
	AI	5,219,739		Tischer et al.	06-15-1993
	AJ	5,326,695		Andersson et al.	07-05-1994
	AK	5,607,918		Eriksson et al.	03-04-1997
	AL	5,776,755		Alitalo et al.	07-07-1998
	AM	98/510133			08/1995
	AN	98/585895			01/1996
	AO	98/601132			02/1996
	AP	98/671573			06/1996
	AQ	98/003491			09/1995
	AR	98/554374			11/1995

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ¹	Number ¹		
M	AS		99/46364	Human Genome Sciences, Inc.	09-16-1999
	AT		98/33917	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.	06-08-1998
	AU		98/07832	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd. Oy	02-26-1998

Examiner Signature	Date Considered
<i>[Signature]</i>	7-15-03

¹Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ¹ See attached Kinds of U.S. Patent Documents. ¹ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ¹ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¹ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ¹ Applicant is to place a check mark here if English language Translation is attached.

Barcode Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0631-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known Application Number: 89/935,726 Filing Date: August 24, 2001 First Named Inventor: HU et al. Group Art Unit: 1647 Examiner Name: Unassigned Attorney Docket Number: PF112P3D1C1	
Sheet	2	of	9

PIPE CITY
JAN 25 2002
PT & TRADEMARK OFFICE

RECEIVED
FEB 04 2002
TECH CENTER 1600/2001

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ¹	Number ² (if known)			
AK	AV		96/39515	Human Genome Sciences, Inc.	12-12-1996	
	AW		96/05856	Human Genome Sciences, Inc.	02-29-1996	
	AX		95/24414	Human Genome Sciences, Inc.	09-14-1995	
	AY		95/19985	Human Genome Sciences, Inc.	07-27-1995	
	AZ		92/14748	American Cyanamid Co.	09-03-1992	
	BA		9-403464	Human Genome Sciences, Inc.	01-31-1996	
	BB		99/21590	Merck & Co.	05-06-1999	
	BC		99/08522	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.	02-25-1999	
	BD		98/56936	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	12-17-1998	
	BE		98/49300	Collateral Therapeutics	11-05-1998	
	BF		98/39035	The Wistar Institute of Anatomy & Biology	09-11-1998	
	BG		98/24811	Zymogenetics, Inc.	06-11-1998	
	BH		98/06844	Human Genome Sciences, Inc.	02-19-1998	
	BI		710696	Genentech, Inc.	09-30-1999	
	BJ		0-476983	Bayne et al.	03-25-1992	
	BK		0-506477	Bayne et al.	09-30-1992	
	BL		97/05250	University of Helsinki	02-13-1997	
	BM		97/09427	Genentech, Inc.	03-13-1997	
	BN		97/17442	Immunex Corporation	05-15-1997	

BEST AVAILABLE COPY

Examiner Signature	<i>Laurel</i>	Date Considered	2-15-02
--------------------	---------------	-----------------	---------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.1). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Brevary Note Statement: This form is estimated to take 10 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/035,726
Filing Date	August 24, 2001
First Named Inventor	HU et al.
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	PF112P3D1C1

Sheet 3 of 9

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
AL	BQ	ACHEN <i>et al.</i> , "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor-2 (Flk1) and VEGF receptor 3 (Flt4)," <i>Proc. Natl. Acad. Sci. (USA)</i> , 95(2): 548-553 (1998).	
	BP	ALDERSON, <i>et al.</i> (1999) Vascular endothelial cell growth factor (VEGF)-2 enhances the development of rat photoreceptor cells in vitro. <i>Keystone Symposia, Ocular Cell and Molecular Biology</i> , 202. (Abstract provided)	
	BQ	ANDERSSON <i>et al.</i> , "Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF," <i>J. Biol. Chem.</i> , 267(16): 11260-11266 (1992).	
	BR	ANDERSSON W.F., "Human gene therapy," <i>Science</i> , 256:808-813 (1992).	
	BS	Aprelikova <i>et al.</i> , "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter," <i>Cancer Research</i> , 52:746-748 (1992).	
	BT	DIGNAM <i>et al.</i> , "Balbiani ring 3 in <i>chironomus tentans</i> encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar," <i>Gene</i> 88:133-140 (1990).	
	BU	FERRARA <i>et al.</i> , "Molecular and biological properties of the vascular endothelial growth factor family of proteins," <i>Endocrine Rev.</i> 13(1): 18-32 (1992).	
	BV	FINNERTY <i>et al.</i> , "Molecular cloning of murine FLT and FLT4," <i>Oncogene</i> 8(11): 2293-2298 (1993).	
	BW	HELDIN <i>et al.</i> , "Structure of platelet-derived growth factor: implications for functional properties," <i>Growth Factors</i> 8:245-252 (1993).	
	BX	EICHMANN <i>et al.</i> , "Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors," <i>Development</i> 125(4): 743-752 (1998).	
	BY	PAJUSOLA <i>et al.</i> , "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines," <i>Cancer Research</i> 52:5738-5743 (1992).	
	BZ	LEUNG <i>et al.</i> , "Vascular endothelial growth factor is a secreted angiogenic mitogen," <i>Science</i> 246:1306-1309 (1989).	
	CA	BREIER <i>et al.</i> , "Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation," <i>Development</i> 114:521-532 (1992).	
	CB	BELL <i>et al.</i> , "Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization," <i>Nucl. Acids Res.</i> 14(21): 8427-8446 (1986).	
	CC	BERSE <i>et al.</i> , Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors," <i>Mol. Biol. Cell.</i> 3:211-220 (1992).	

Examiner Signature	Date Considered
<i>[Signature]</i>	7-15-03

¹Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ¹ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

BEST AVAILABLE COPY

Please type a plus sign (+) inside this box



PTO/SB/08 (03/00)

Approved for use through 10/31/2002. OMB 0651-0047

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/935,726
Filing Date	August 24, 2001
First Named Inventor	HU et al.
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	PF112P3D1C1

Sheet 4 of 9



RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
AL	CD	BETSHOLTZ <i>et al.</i> , "cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines," <i>Nature</i> 320:695-699 (1986).	
	CE	CLAFFEY <i>et al.</i> , "Vascular endothelial growth factor," <i>J. Biol. Chem.</i> 267(23): 16317-16322 (1992).	
	CF	CORSON <i>et al.</i> , "Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end," <i>Genomics</i> 17:476-484 (1993).	
	CG	FERRARA <i>et al.</i> , "The vascular endothelial growth factor family of polypeptides," <i>J. Cellular Biochemistry</i> 47:211-218 (1991).	
	CH	GEORGE <i>et al.</i> , "Current Methods in Sequence Comparison and Analysis," <i>Macromolecular Seq. and Syn. Selected Meth - Application</i> (Alan R. Liss), pp. 127-149 (1988).	
	CI	HU <i>et al.</i> , "A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial smooth muscle cells," <i>FASEB J.</i> 11:498-504 (1997).	
	CJ	JOUKOV <i>et al.</i> , "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases," <i>EMBO J.</i> 15(2): 290-298 (1996).	
	CK	JOUKOV <i>et al.</i> , "Proteolytic processing regulates receptor specificity and activity of VEGF-C," <i>EMBO J.</i> 16(13): 3898-3911 (1997).	
	CL	KALPAINEN <i>et al.</i> , "The related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells," <i>J. Exp. Med.</i> 178:2077-2088 (1993).	
	CM	KECK <i>et al.</i> , "Vascular permeability factor, an endothelial cell mitogen related to PDGF," <i>Science</i> 246: 1309 (1989).	
	CN	KINGSLEY, D., "The TGF- β superfamily: new members, new receptors, and new genetic tests of function in different organisms," <i>Genes & Development</i> 8: 133-146 (1994).	
	CO	KUKK <i>et al.</i> , "VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development," <i>Development</i> 122: 3829-37 (1996).	
	CP	LEE <i>et al.</i> , "Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4," <i>Proc. Natl. Acad. Sci. (USA)</i> , 93:1988-1992 (1996).	
	CQ	MAGLIONE <i>et al.</i> , "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14," <i>Oncogene</i> 8:925-931 (1993).	

BEST AVAILABLE COPY

Examiner Signature	<i>Lachar</i>	Date Considered	9-15-02
--------------------	---------------	-----------------	---------

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Unique citation designation number. * Applicant is to place a check mark here if English language Translation is attached.

Random Hour Statement: This form is estimated to take 10 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box



PTO/SB/08 (07-00)

Approved for use through 10/1/2002. OMB 0611-0007
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substrate for form 1449PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known Application Number: 09/935,726 Filing Date: August 24, 2001 First Named Inventor: HU et al. Group Art Unit: 1647 Examiner Name: Unassigned Attorney Docket Number: PF112P3D1C1	
Sheet	5	of	9

OIPE
 JAN 25 2002
 TRADEMARK OFFICE

RECEIVED

FEB 04 2002
 TECH CENTER 1600/2900

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
CR		MAGLIONE et al., "Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88:9267-9271 (1991).
CS		MASSAGUE, J., "The transforming growth factor-beta family," <i>Annu. Rev. Cell Biol.</i> 6:597-641 (1990).
CT		MATTHEWS et al., "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88:9026-9030 (1991).
CU		MILLAUER et al., "High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis," <i>Cell</i> 72:835-846 (1993).
CV		MILLAUER et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant," <i>Nature</i> 367:576-579 (1994).
CW		OLTVAL et al., "Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death," <i>Cell</i> 74:609-619 (1993).
CX		PAULSSON et al., "The balbiani ring 3 gene in <i>chironomus tentans</i> has a diverged repetitive structure split by many introns," <i>J. Mol. Biol.</i> 211:331-349 (1990).
CY		PAJUSOLA et al., "Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts," <i>Oncogene</i> 8:2931-2937 (1993).
CZ		TISCHER et al., "Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family," <i>Biochem. & Biophys. Res. Comm.</i> 165(3): 1198-1206 (1989).
DA		TANAKA et al., "DNA sequence encoding the amino-terminal region of the human c-src protein: implications of sequence divergence among src-type kinase oncogenes," <i>Mol. Cell Biol.</i> 7(5): 1978-1983 (1987).
DB		TERMAN et al., "Identification of a new endothelial cell growth factor receptor tyrosine kinase," <i>Oncogene</i> 6:1677-1683 (1991).
DC		TERMAN et al., "Identification of the kdr tyrosine kinase as a receptor for vascular endothelial cell growth factor," <i>Biochem. Biophys. Res. Commun.</i> 187(3): 1579-1586 (1992).
DD		TSUJIMOTO et al., "Analysis of the structure, transcripts, and protein products of <i>bel-2</i> , the gene involved in human follicular lymphoma," <i>Proc. Natl. Acad. Sci. (USA)</i> , 83:5214-5218 (1986).
DE		TISCHER et al., "The Human Gene for Vascular Endothelial Growth Factor," <i>J. Biol. Chem.</i> 266(18): 11947-11954 (1991).
DF		FRIEDMAN, T., "A brief history of gene therapy," <i>Nat. Genetics</i> 2:93-98 (1992).

BEST AVAILABLE COPY

Examiner Signature	Date Considered
<i>[Signature]</i>	9/15/02

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Attach copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box



PTO/SB/08 (03-07)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

Substance for Exam 14497710

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 9

Complete if Known

Application Number 09/935,726
Filing Date August 24, 2001
First Named Inventor HU et al.
Group Art Unit 1647
Examiner Name Unassigned
Attorney Docket Number PF112F3D1C1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
M	DG	WILLIAMS, R.S. "Southwestern internal medicine conference: prospects for gene therapy of ischemic heart disease," <i>Am. J. Med. Sci.</i> 306(2): 129-136 (1993).
	DH	HOCKEL et al., "Therapeutic angiogenesis," <i>Arch. Surg.</i> 128:423-429 (1993).
	DI	GUZMAN et al., "Efficient gene transfer into myocardium by direct injection of adenovirus vectors," <i>Circ. Res.</i> 73:1202-1207 (1993).
	DJ	BELLOMO et al., "Mice Lacking the Vascular Endothelial Growth Factor-B Gene (Vegfb) Have Smaller Hearts, Dysfunctional Coronary Vasculature, and Impaired Recovery From Cardiac Ischemia," <i>Circ. Research</i> 89(2): e29-e35 (2000).
	DK	COCKERILL et al., "Angiogenesis: Models and Modulators" <i>Intl. Rev. Cytology</i> 159:113-160 (1995).
	DL	GAMBLE et al., "Regulation of In Vitro Capillary Tube Formation by Anti-Integrin Antibodies," <i>J. Cell. Bio.</i> 121(4): 931-943 (1993).
	DM	GOLDSPIEL et al., "Human Gene Therapy," <i>Clinical Pharmacy</i> 12: 488-505 (1993).
	DN	GRIMMOND et al., "Cloning and Characterization of a Novel Human Gene Related to Vascular Endothelial Growth Factor," <i>Genome Research</i> 6:124-131 (1996).
	DO	HYDE et al., "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," <i>Nature</i> 362: 250-255 (1993).
	DP	KAY et al., "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," <i>Science</i> 262:117-119 (1993).
L	DQ	KOLODKA et al., "Hepatic Gene Therapy: Efficient Retroviral-Mediated Gene Transfer into Rat Hepatocytes in Vivo," <i>Somatic Cell and Molecular Genetics</i> 19(5): 491-497 (1993).
	DR	LITWIN et al., "Role of Cytokines in Endothelial Cell Functions," <i>Human Cytokines</i> 10: 119-129.
M	DS	SHIBUYA et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>fli</i>) closely related to the <i>fms</i> family," <i>Oncogene</i> 519-524 (1990).
	DT	SILINS et al., "Analysis of the Promoter Region of the Human VEGF-Related Factor Gene," <i>Biochem. Biophys. Res. Comm.</i> 230: 413-418 (1997).
	DU	STEWART et al., "Insulin delivery by somatic cell gene therapy," <i>J of Mol. Endocrinology</i> 11: 335-341 (1993).
	DV	TOWNSON et al., "Characterization of the Murine VEGF-Related Factor Gene," <i>Biochem. & Biophys. Res. Comm.</i> 220: 922-928 (1996).
	DW	WALSH et al., "Gene Therapy for Human Hemoglobinopathies," <i>P.S.E.B.M.</i> 204: 289-300.
N	DX	YOUREY, et al. (2000) Vascular Endothelial Cell Growth Factors Promote the In Vitro Development of Rat Photoreceptor Cells. <i>J. Neuroscience</i> , 20: 6781 - 6788.

Examiner Signature

[Signature]


Date Considered

9.15.02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with near communication to applicant.

*Unique citation designation number. * Applicant is to place a check mark here if English language Translation is attached.

Search How Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Communications for Patent, Washington, DC 20231.



RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

BEST AVAILABLE COPY

Please type a plus sign (+) inside this box



PTO/SB/08 (04-70)

Approved for use through 10/31/2002. OMB 0631-0011

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/935.726
		Filing Date	August 24, 2001
		First Named Inventor	HU et al.
		Group Art Unit	1647
		Examiner Name	Unassigned
Sheet 7 of 9	Attorney Docket Number	PF112P3D1C1	

IP E JC177
JAN 25 2002
PATENT & TRADEMARK OFFICE

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
PK	DY	YOUREY, et al. (1999) Vascular Endothelial Cell Growth Factor (VEGF)-2 Enhances the Development of Rat Photoreceptor Cells In Vitro. Soc. Cell Biology, 227. (Abstract provided)
	DZ	GenBank Accession No. X68203, APRELIKOVA et al., "H.sapiens mRNA for FLT4, class III receptor tyrosine kinase," November 30, 1993.
	EA	GenBank Accession No. M95200, CLAFFEY et al., "Mouse vascular endothelial growth factor mRNA, complete cds," April 27, 1993.
	EB	GenBank Accession No. M24160, DIGNAM et al., "C.tentans 185-kd secretory protein (sp185) mRNA, partial cds, clone pCt1185," April 26, 1993.
	EC	GenBank Accession No. M24276, DIGNAM et al., "C.tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCt140.1," April 26, 1993.
	ED	GenBank Accession No. M24277, DIGNAM et al., "C.tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCt140.2," April 26, 1993.
	EE	GenBank Accession No. D88689, FINNERTY et al., "Mus musculus mRNA for flt-1, complete cds," April 14, 2000.
	EF	GenBank Accession No. L07296, FINNERTY et al., "Mus musculus receptor tyrosine kinase (FLT4) mRNA, complete cds," August 9, 1993.
	EG	GenBank Accession No. X54936, MAGLIONE et al., "H.sapiens mRNA for placenta growth factor (PIGF)," November 12, 1991.
	EH	GenBank Accession No. S57152, MAGLIONE et al., "Homo sapiens placenta growth factor 2 (PIGF-2) gene, partial cds," March 5, 2001.
	EI	GenBank Accession No. X59397, MATTHEWS et al., "Mouse Flk-1 mRNA for a tyrosine kinase receptor," November 6, 1991.
	EJ	GenBank Accession No. X52263, PAULSSON et al., "C.tentans balbiani ring 3 (BR3) gene," December 18, 1992.
	EK	GenBank Accession No. M63971, TISCHER et al., "Human vascular endothelial growth factor gene, exon 1," August, 1993.
	EL	GenBank Accession No. M63972, TISCHER et al., "Human vascular endothelial growth factor gene, exon 2," August 3, 1993.
	EM	GenBank Accession No. M63973, TISCHER et al., "Human vascular endothelial growth factor gene, exon 3," August 3, 1993.
	EN	GenBank Accession No. M63974, TISCHER et al., "Human vascular endothelial growth factor gene, exon 4," August 3, 1993.
	EO	GenBank Accession No. M63975, TISCHER et al., "Human vascular endothelial growth factor gene, exon 5," August 3, 1993.

Examiner Signature	Date Considered
<i>Laurel</i>	7/15/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Unique citation designation number. * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

BEST AVAILABLE COPY

Please type a plus sign (+) inside this box



PTO/SB/03 (Rev. 03/01)

Approved for use through 10/31/2002. OMB 063-0011

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 9

Complete if Known

Application Number	09/935,716
Filing Date	August 24, 2001
First Named Inventor	HU et al.
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	PF112P3D1C1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
M	EP	GenBank Accession No. M63976, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 6," August 3, 1993.	
	EQ	GenBank Accession No. M63977, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 7," August 3, 1993.	
	ER	GenBank Accession No. M63978, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 8," August 3, 1993.	
	ES	GenBank Accession No. M27281, KECK <i>et al.</i> , "Human vascular permeability factor mRNA, complete cds," August 3, 1993.	
	ET	GenBank Accession No. X04571, BELL <i>et al.</i> , "Human mRNA for kidney epidermal growth factor (EGF) precursor," March 21, 1995.	
	EU	GenBank Accession No. X63556, CORSON <i>et al.</i> , "H. sapiens mRNA for fibrillin," February 17, 1997.	
	EV	GenBank Accession No. L19896, CORSON <i>et al.</i> , "Human fibrillin (FBN1) gene, 5' end including alternative exons A, B, and C, and exon M," November 8, 1994.	
	EW	GenBank Accession No. L04947, TERMAN <i>et al.</i> , "Homo sapiens (clones BT3.081.8, BT3.129.5 and BT4.169)," January 6, 1995.	
	EX	GenBank Accession No. M16237, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 2," January 13, 1995.	
	FY	GenBank Accession No. M16243, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 3," January 13, 1995.	
	EZ	GenBank Accession No. M16244, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 4," January 13, 1995.	
	FA	GenBank Accession No. M16245, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 5," January 13, 1995.	
	FB	GenBank Accession No. K03212, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 6," January 13, 1995.	
	FC	GenBank Accession No. K03213, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 7," January 13, 1995.	
	FD	GenBank Accession No. K03214, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 8," January 13, 1995.	
	FE	GenBank Accession No. K03215, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 9," January 13, 1995.	
	FF	GenBank Accession No. K03216, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 10," January 13, 1995.	
	FG	GenBank Accession No. K03217, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 11," January 13, 1995.	

Examiner Signature

David

Date Considered

7/5/93

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Includes copy of this form with each communication to applicant.

*Unique citation designation number. *Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

BEST AVAILABLE COPY

Please type a plus sign (+) inside this box



PTO/SB/08 (01-00)

Approved for use through 10/11/2002. OMB 065 (2001)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/935,726
Filing Date	August 24, 2001
First Named Inventor	HU et al.
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	PF112PJD1C1

Sheet 9 of 9

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
AL	FH	GenBank Accession No. K03218, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 12," January 13, 1995.
	FI	GenBank Accession No. M13994, TSUJIMOTO <i>et al.</i> , "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-2-alpha protein, complete cds," October 31, 1994.
	FJ	GenBank Accession No. M13995, TSUJIMOTO <i>et al.</i> , "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-3-beta protein, complete cds," October 31, 1994.
	FK	GenBank Accession No. L22473, OLTVAI <i>et al.</i> , "Human Bax alpha mRNA, complete cds," December 15, 1993.
	FL	GenBank Accession No. L22474, OLTVAI <i>et al.</i> , "Human Bax beta mRNA, complete cds," December 13, 1993.
	FM	GenBank Accession No. AJ000185, ACHEN <i>et al.</i> , "Homo Sapiens mRNA for vascular endothelial growth factor-D," February 11, 1998.
	FN	International Search Report, Application No. PCT/US99/05021.
	FO	International Search Report, Application No. PCT/US94/05291.

BEST AVAILABLE COPY

Examiner Signature	<i>David</i>	Date Considered	7-15-03
--------------------	--------------	-----------------	---------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

DIPE
JAN 15 2002
U.S. PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 04 2002
TECH CENTER 1600/2800

RECEIVED

MAR 14 2002

Please type a plus sign (+) inside this box ☐

Approved for use through 10/1/2001 by the U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

TECHNICAL STAFF 600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to furnish information unless it contains a valid OMB control number.

Solutions for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known Application Number: 09/935,726 Filing Date: August 24, 2001 First Named Inventor: Hu, et al. Group Art Unit: 1647 Examiner Name: <i>[Signature]</i> Attorney Docket Number: PF112P3D1C1	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ¹ (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ¹	Number ²	Kind Code ³ (if known)			
<i>M</i>	FP	EP	0476983	A1	Merck & Co., Inc.	03-25-1992	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	FQ	International Search Report, Application No. PCT/US01/24656 mailed on Dec. 12, 2001.

Examiner Signature: <i>[Signature]</i>	Date Considered: 9-15-01
--	--------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

BEST AVAILABLE COPY